- Home
- WVE
as 11-15-2024 4:00pm EST
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
| Founded: | 2012 | Country: | Singapore |
| Employees: | N/A | City: | SINGAPORE |
| Market Cap: | 2.4B | IPO Year: | 2015 |
| Target Price: | $21.30 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.50 - $16.74 | Next Earning Date: | 11-12-2024 |
| Revenue: | $53,610,000 | Revenue Growth: | -37.29% |
| Revenue Growth (this year): | -37.75% | Revenue Growth (next year): | -5.48% |
Stock Insider Trading Activity of Wave Life Sciences Ltd. (WVE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Francis Chris | WVE | See Remarks | Nov 8 '24 | Sell | $16.00 | 36,000 | $576,000.00 | 0 | |
| BOLNO PAUL | WVE | President and CEO | Oct 16 '24 | Sell | $15.00 | 90,474 | $1,357,110.00 | 268,585 | |
| GSK plc | WVE | 10% Owner | Sep 27 '24 | Buy | $8.00 | 2,791,930 | $22,335,440.00 | 16,775,691 | |
| Moran Kyle | WVE | Chief Financial Officer | Sep 25 '24 | Sell | $9.00 | 17,146 | $154,314.00 | 19,777 |
Latest Wave Life Sciences Ltd. News
WVE Breaking Stock News: Dive into WVE Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Wave Life Sciences to Present at Jefferies London Healthcare Conference
Simply Wall St.
2 days ago
Wave Life Sciences Ltd. (NASDAQ:WVE) Released Earnings Last Week And Analysts Lifted Their Price Target To US$22.20
Simply Wall St.
3 days ago
Wave Life Sciences Third Quarter 2024 Earnings: Misses Expectations
GuruFocus.com
4 days ago
WAVE Life Sciences Ltd (WVE) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...
MT Newswires
5 days ago
--Truist Securities Adjusts Price Target on Wave Life Sciences to $36 From $17, Keeps Buy Rating
Zacks
5 days ago
Wave Life Sciences (WVE) Reports Q3 Loss, Lags Revenue Estimates
MT Newswires
5 days ago
Wave Life Sciences Swings to Q3 Loss
Associated Press Finance
5 days ago
Wave Life Sciences: Q3 Earnings Snapshot
Compare WVE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "WVE Wave Life Sciences Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.